Company intelligence / Profile preview

Lizhuo Pharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Lizhuo Pharmaceutical (Xiamen) has several products approved in China and the US (e.g., Perfluoropropane-albumin microspheres for imaging, aripiprazole for schizophrenia), with additional clinical-stage programs in neurology and cardiovascular areas. Shanghai Lizhuo specializes in pharmaceutical intermediates, supporting global pharma R&D with custom synthesis capabilities

Therapeutic areas: PsychiatryCardiovascularOtherOncologyNeurology
Modalities: Small moleculeContrast agent
Industry: Biotech

Partnerships

Academic collaborations with Shanghai Institute of Organic Chemistry, Chinese Academy of SciencesZhejiang UniversityZhejiang University of Technology

Beyond the preview

Go deeper on Lizhuo Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lizhuo Pharmaceutical.

Explore the full profile